Biomerica reports developments in diagnostic-guided therapies and medical diagnostic products used in point-of-care, home, physician-office and clinical laboratory settings. The company focuses on gastrointestinal and inflammatory diseases, with recurring updates around inFoods® IBS, a finger-stick blood test used to identify individual food triggers for IBS dietary guidance, and Hp Detect™/hp+detect™, an H. pylori stool antigen diagnostic.
Biomerica news also covers commercialization and regulatory activity for products such as EZ Detect™, an at-home colorectal disease screening test, along with international distribution, laboratory partnerships, reimbursement and coding updates, clinical data presentations, fiscal results and the company’s CDMO services activity.
Biomerica Inc. (NASDAQ: BMRA) announced the filing of a new three-year shelf registration statement on Form S-3 with the SEC, replacing the previous registration effective since July 2017. This move offers the company flexibility for future capital market access. Additionally, 571,429 shares of common stock are being registered on behalf of Palm Global Master Small Cap Master Fund LP, related to their previous purchase of convertible preferred stock. Biomerica has no immediate plans to offer any securities under this new registration.
Biomerica (NASDAQ: BMRA) has partnered with the University of Texas Health Science Center at Houston to advance its InFoods® diagnostic-guided therapy aimed at alleviating symptoms of Irritable Bowel Syndrome (IBS). With over 45 million Americans affected by IBS, the trial focuses on identifying specific foods that trigger symptoms. The clinical trial is set to complete within 6 months, with the potential for a pivotal trial afterward for FDA submission. The InFoods® therapy is non-pharmaceutical, addressing the root causes of IBS while being compatible with existing treatments.
Biomerica (NASDAQ: BMRA) has submitted an EUA application to the FDA for an ELISA lab-based serology blood test to detect COVID-19 antibodies. This test aims to identify prior infections, supporting the reopening of economies. It boasts 100% specificity and no cross-reactivity. Biomerica plans to manufacture this test at its Irvine facility, which simplifies blood collection using a proprietary device. This is the third COVID-19 antibody test from Biomerica, adding to existing finger-prick tests sold internationally.
Biomerica (NASDAQ: BMRA) has secured its first Japanese patent for its InFoods® IBS Diagnostic Guided Therapy technology, aimed at alleviating symptoms of Irritable Bowel Syndrome (IBS) by identifying patient-specific food triggers. Approximately 45 million Americans and 19 million Japanese suffer from IBS, which costs the U.S. healthcare system an estimated $30 billion annually. The company has partnered with Mayo Clinic and other leading medical centers to conduct clinical trials for this innovative therapy, which may enhance treatment options without drug-type side effects.
Biomerica has launched a new high-volume production test for COVID-19 IgG/IgM, receiving CE mark approval. This rapid test, requiring only a finger prick and yielding results in 10 minutes, is designed for international markets, with a unit price of $10. The company has started shipping this test to distributors serving NATO and government agencies in Germany, Switzerland, and the Netherlands. Additionally, Biomerica is expanding its patent applications for a simplified blood sample collection method for future tests, aiming to meet international demand while remaining environmentally friendly.